Latest Conference Articles

January 11th 2016, 10:27am

Genitourinary Cancers Symposium (ASCO GU)

A selective class I oral histone deactylase inhibitor may increase the antitumor effect of high- dose interleukin-2 in renal cell carcinoma.

January 11th 2016, 10:25am

Genitourinary Cancers Symposium (ASCO GU)

Nivolumab’s second-line survival benefit in renal cell carcinoma was consistent across subgroups categorized by patient risk status, prior treatment, and degree of metastases, according to an update of the phase III CheckMate-025 trial.

January 11th 2016, 10:23am

Genitourinary Cancers Symposium (ASCO GU)

Daniel A. Hamstra, MD, PhD, assistant professor of Radiation Oncology, University of Michigan Health System, discusses clinical trials comparing the length of radiation treatments for patients with prostate cancer.

January 9th 2016, 5:36pm

Genitourinary Cancers Symposium (ASCO GU)

Hypofractionated radiotherapy demonstrated similar toxicity and was noninferior to standard radiation therapy for preventing PSA increases or disease recurrences for men with intermediate-risk prostate cancer.

January 9th 2016, 5:30pm

Genitourinary Cancers Symposium (ASCO GU)

Second-line treatment with atezolizumab (MPDL3280A) led to durable responses in patients with locally advanced or metastatic urothelial carcinoma.

January 9th 2016, 2:31pm

Genitourinary Cancers Symposium (ASCO GU)

Adding celecoxib and zoledronic acid to standard treatment extended survival in men with metastatic prostate cancer commencing first-line hormone therapy, according to updated data from the STAMPEDE trial.

January 9th 2016, 1:49pm

Genitourinary Cancers Symposium (ASCO GU)

The addition of the CTLA-4 inhibitor ipilimumab to cisplatin and gemcitabine did not significantly improve overall survival for patients with metastatic urothelial cancer.

January 9th 2016, 11:28am

Genitourinary Cancers Symposium (ASCO GU)

The investigational anti-PD-L1 antibody avelumab demonstrated antitumor activity with an acceptable safety profile in a phase Ib trial of patients with metastatic urothelial cancer refractory to standard therapy.

January 9th 2016, 9:29am

Genitourinary Cancers Symposium (ASCO GU)

Elizabeth Plimack, MD, MS, Associate Professor, Director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses immunotherapy in bladder cancer.

January 9th 2016, 7:43am

Genitourinary Cancers Symposium (ASCO GU)

Adam S. Kibel, MD, disease center leader, urology chief, urologic surgery, Brigham and Women's Hospital, professor of Surgery, Harvard Medical School, Dana-Farber Cancer Institute, discusses take-home messages for community oncologists out of the 2016 Genitourinary Cancers Symposium.

January 8th 2016, 3:12pm

Genitourinary Cancers Symposium (ASCO GU)

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the significance of the CheckMate-025 for renal cell carcinoma.

January 8th 2016, 1:38pm

Genitourinary Cancers Symposium (ASCO GU)

A post hoc analysis of the COU-AA-302 clinical trial suggests that docetaxel has antitumor activity as first subsequent therapy following disease progression with abiraterone acetate in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer.

January 8th 2016, 8:38am

Genitourinary Cancers Symposium (ASCO GU)

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses treatment advancements in small cell urothelial cancer.

January 4th 2016, 3:03pm

Genitourinary Cancers Symposium (ASCO GU)

Aspirin’s benefits may now extend to reducing the risk of deadly prostate cancer, according to the results of an observational study which found that previously undiagnosed men who took regular aspirin had a 24% lower risk of developing a lethal form of the disease.

January 4th 2016, 3:01pm

Genitourinary Cancers Symposium (ASCO GU)

The non-invasive liquid biopsy, if validated, could lead to the development of a personalized selection tool in men with advanced prostate cancer.

January 4th 2016, 3:00pm

Genitourinary Cancers Symposium (ASCO GU)

Cabozantinib significantly improved progression-free survival versus everolimus in patients with renal cell carcinoma regardless of the degree of metastases, type or number of prior treatments, or patient risk status.

December 14th 2015, 4:15pm

San Antonio Breast Cancer Symposium

Palbociclib enhances cell cycle control when added to anastrazole in the neoadjuvant setting in women with ER-positive primary breast cancer.

December 12th 2015, 10:04am

San Antonio Breast Cancer Symposium

The PD-1 inhibitor pembrolizumab had an overall response rate of 12% in PD-L1–positive patients with ER-positive/HER2-negative advanced breast cancer.

December 12th 2015, 8:25am

San Antonio Breast Cancer Symposium

The oral pan-HER TKI neratinib continued to show similar rates of disease-free survival for patients with HER2-positive early-stage breast cancer at a 3-year analysis of the phase III ExteNET trial.

December 11th 2015, 2:23pm

San Antonio Breast Cancer Symposium

Patricia Ganz, MD, UCLA Jonsson Comprehensive Cancer Center, discusses a study comparing anastrozole versus tamoxifen in patients with ductal carcinoma in situ (DCIS) breast cancer.